Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Market Update

Julia Lee
March 31, 2017

Market Update

Julia Lee
March 30, 2017

March Overview

Julia Lee
March 28, 2017

Market Update

Julia Lee
March 27, 2017

Market Update

Julia Lee
March 23, 2017

Market Update

Julia Lee
March 22, 2017

Market Update

Julia Lee
March 20, 2017

Market Update

Julia Lee
March 17, 2017

Market Update

Julia Lee
March 16, 2017

Market Update 15 March 2017

Julia Lee
March 15, 2017

How to review your portfolio

Bell Direct
March 14, 2017